The survival data showed that HNSCC patients with HPV+ status defined as HPV+/p16+ have a better 5-year OS and DFS than subgroups with HPV−/p16−, HPV+/p16− and HPV−/p16+. This evidence concerns the gene CDKN2A and head and neck squamous cell carcinoma.